Arthur Tzianabos, Ph.D., June Lee, MD, FACCP, and Joseph Loscalzo, MD, PhD Join 5AM Ventures

News
2022
2021
Archive

December 16, 2021

Pear Therapeutics and Crossroads Treatment Centers to Provide More Patients Access to Prescription Digital Therapeutics as Standard of Care for the Treatment of Substance Use Disorders
December 14, 2021

Cidara Therapeutics and Mundipharma Announce Positive Topline Results From the Global Phase 3 Pivotal ReSTORE Tiral of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
December 10, 2021

CinCor Pharma, Inc., Doses First Patient in HALO, a Phase 2 Clinical Trial Evaluating CIN-107, a Selective Aldosterone Synthase Inhibitor, in Patients with Uncontrolled Hypertension and High Plasma Aldosterone
December 8, 2021

IDEAYA Reports Clinical Data from Phase 2 Expansion Dose of Darovasertib and Crizotinib Synthetic Lethal Combination in Heavily Pre-Treated Metastatic Uveal Melanoma
December 6, 2021

Pear Therapeutics and Thimble Point Announce Closing of Business Combination to Create Publicly Traded Prescription Digital Therapeutics Company
December 3, 2021

CAMP4 Presents In Vivo Data Supporting Novel Therapeutic Strategy for Dravet Syndrome at American Epilepsy Society Annual Meeting
December 3, 2021

Rallybio Reports Positive Data in Its Clinical Program for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
November 22, 2021

Pear Therapeutics Receives FDA Breakthrough Device Designation for Prescription Digital Therapeutics Candidate to Treat Alcohol Use Disorder
November 19, 2021

Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast Cancer Symposium
November 17, 2021

Novome Biotechnologies Reports Positive Results from a Phase 1 Study of NOV-001

1
2
3
…
16
Next Page »

© 2022 5AM Venture Management LLC